A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate-to-Severe Plaque Psoriasis

Eli Lilly Japan K.K.0 个研究点目标入组 20 人开始时间: 2017年1月31日最近更新: 2023年10月17日

试验速览

暂无简介。

•Present with chronic plaque psoriasis for at least 6 months prior to baseline and meet the following criteria: plaque psoriasis involving 10% BSA or more, PASI score 12 or more, sPGA score of 3 or more.

•-Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data.
•-Breastfeeding or nursing (lactating) women.
•-Have had serious, opportunistic, or chronic/recurring infection within 6 months prior to screening.
•-Have received live vaccine(s) (included attenuated live vaccines) within 1 month of screening or intend to during the study.
•-Have any other skin conditions (excluding psoriasis) that would affect interpretation of the results.
•-Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days prior to baseline.
•-Have received topical psoriasis treatment within 14 days prior to baseline.
•-Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17 targeting biologics within 8 weeks prior to baseline.
•-Have previous exposure to any biologic therapy targeting IL-23 (including ustekinumab), either licensed or investigational (previous briakinumab use is permitted).

发起方